Relay Therapeutics (NASDAQ:RLAY) Insider Peter Rahmer Sells 748 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Peter Rahmer sold 748 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $18.61, for a total transaction of $13,920.28. Following the sale, the insider owned 228,165 shares of the company’s stock, valued at $4,246,150.65. The trade was a 0.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Peter Rahmer also recently made the following trade(s):

• On Tuesday, June 30th, Peter Rahmer sold 50,000 shares of Relay Therapeutics stock. The stock was sold at an average price of $19.09, for a total transaction of $954,500.00.

Relay Therapeutics Stock Performance

NASDAQ RLAY opened at $19.45 on Friday. The stock has a market capitalization of $3.73 billion, a P/E ratio of -12.39 and a beta of 1.67. Relay Therapeutics, Inc. has a 1 year low of $3.03 and a 1 year high of $20.79. The business’s fifty day moving average is $17.06 and its two-hundred day moving average is $13.03.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The firm had revenue of $3.00 million during the quarter, compared to analyst estimates of $5.58 million. On average, research analysts forecast that Relay Therapeutics, Inc. will post -1.57 earnings per share for the current year.

Key Stories Impacting Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Analysts at Zacks said Relay Therapeutics may beat consensus earnings expectations in its upcoming report, potentially providing a near-term catalyst for RLAY. The preview cites favorable expectations but does not represent an actual earnings result. Relay Therapeutics Expected to Beat Earnings Estimates
• Positive Sentiment: Relay’s breast cancer program has helped revitalize investor interest in the clinical-stage biotechnology company, although the opportunity faces intense competition from other drug developers. Relay Therapeutics Revitalized by Breast Cancer Program
• Neutral Sentiment: Relay Therapeutics will release second-quarter 2026 financial results and corporate highlights after the market closes on August 6. Investors will likely focus on pipeline progress, cash resources and guidance for upcoming clinical development. Relay Therapeutics to Announce Second-Quarter Results
• Neutral Sentiment: Three insiders, including CFO Thomas Catinazzo, sold a combined 4,444 shares at an average price of $18.61. The filings state the sales were made to cover tax withholding obligations tied to vested equity awards, and each insider retained a substantial ownership position, reducing the bearish significance.
• Negative Sentiment: The company remains a clinical-stage biotechnology firm, so its valuation depends heavily on successful development and commercialization of its pipeline. Competitive pressure in breast cancer could limit the potential upside and increase execution risk.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on RLAY shares. JPMorgan Chase & Co. initiated coverage on Relay Therapeutics in a research report on Wednesday, July 8th. They issued an “overweight” rating and a $28.00 price target for the company. Raymond James Financial restated a “strong-buy” rating on shares of Relay Therapeutics in a report on Tuesday, May 19th. The Goldman Sachs Group upped their price objective on shares of Relay Therapeutics from $22.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Wells Fargo & Company raised their target price on shares of Relay Therapeutics from $17.00 to $21.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Finally, Citigroup reissued an “outperform” rating on shares of Relay Therapeutics in a research report on Wednesday, May 20th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, Relay Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $24.92.

Institutional Investors Weigh In On Relay Therapeutics

Institutional investors have recently made changes to their positions in the company. KBC Group NV bought a new stake in shares of Relay Therapeutics in the 1st quarter valued at approximately $34,000. Torren Management LLC bought a new position in Relay Therapeutics during the fourth quarter valued at approximately $30,000. Smartleaf Asset Management LLC raised its position in Relay Therapeutics by 288.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after acquiring an additional 3,287 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Relay Therapeutics during the fourth quarter valued at approximately $46,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Relay Therapeutics by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company’s stock valued at $71,000 after acquiring an additional 1,757 shares during the last quarter. 96.98% of the stock is currently owned by institutional investors and hedge funds.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.